Sjuts Dustin S

CIK 00017962241 companyNEWARK, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001796224

Recent Transactions

42 trades

Sale
Revance Therapeutics, Inc.
Common Stock
2024-03-18$5.04/sh−9,211→ 167,550 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2024-03-15$5.30/sh−2,967→ 176,761 total
Award
Revance Therapeutics, Inc.
Common Stock
2024-02-29+22,110→ 179,728 total
Award
Revance Therapeutics, Inc.
Common Stock
2023-12-31$7.47/sh+264→ 157,618 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2023-12-15$8.08/sh−4,712→ 157,354 total
Award
Revance Therapeutics, Inc.
Common Stock
2023-08-11+22,620→ 170,967 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2023-08-11$18.91/sh−8,901→ 162,066 total
Award
Revance Therapeutics, Inc.
Common Stock
2023-06-30$15.61/sh+1,000→ 148,347 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-06-09$30.82/sh−5,000→ 147,347 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-05-15$34.55/sh−21,015→ 152,347 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2023-03-15$30.65/sh−2,967→ 120,967 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-03-09$31.59/sh−21,508→ 123,934 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2023-02-15$33.21/sh−2,766→ 93,046 total
Award
Revance Therapeutics, Inc.
Employee Stock Option (Right to Buy)
2023-01-31+43,255→ 43,255 total
Award
Revance Therapeutics, Inc.
Common Stock
2022-12-31$12.18/sh+605→ 95,812 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2022-12-15$21.50/sh−2,916→ 95,207 total
Award
Revance Therapeutics, Inc.
Common Stock
2022-09-22+52,396→ 145,442 total
Award
Revance Therapeutics, Inc.
Common Stock
2022-06-30$11.75/sh+1,000→ 98,123 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2022-03-15$15.79/sh−1,835→ 97,123 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2022-02-15$13.35/sh−295→ 98,958 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2022-02-15$13.35/sh−2,134→ 99,253 total
Award
Revance Therapeutics, Inc.
Employee Stock Option (Right to Buy)
2022-02-02+57,016→ 57,016 total
Award
Revance Therapeutics, Inc.
Common Stock
2022-02-02+52,395→ 173,362 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2021-12-15$15.92/sh−513→ 101,387 total
Award
Revance Therapeutics, Inc.
Common Stock
2021-11-09+35,920→ 101,900 total
Other
Revance Therapeutics, Inc.
Common Stock
2021-06-30$24.09/sh+882→ 65,980 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2021-04-15$28.16/sh−411→ 65,098 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2021-02-15$28.97/sh−2,135→ 65,509 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2021-02-15$28.97/sh−275→ 67,644 total
Award
Revance Therapeutics, Inc.
Employee Stock Option (Right to Buy)
2021-02-02+40,925→ 40,925 total
Award
Revance Therapeutics, Inc.
Common Stock
2021-02-02+22,620→ 67,919 total
Other
Revance Therapeutics, Inc.
Common Stock
2020-12-31$21.36/sh+348→ 45,299 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2020-12-15$26.75/sh−562→ 44,951 total
Award
Revance Therapeutics, Inc.
Common Stock
2020-09-30+17,500→ 51,564 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2020-09-30$25.14/sh−6,051→ 45,513 total
Other
Revance Therapeutics, Inc.
Common Stock
2020-06-30$13.80/sh+1,000→ 34,064 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2020-04-15$14.80/sh−432→ 33,064 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2020-02-15$25.33/sh−288→ 33,496 total
Award
Revance Therapeutics, Inc.
Common Stock
2020-01-23+20,000→ 33,784 total
Award
Revance Therapeutics, Inc.
Employee Stock Option (Right to Buy)
2020-01-23$22.32/sh+100,000→ 100,000 total
Other
Revance Therapeutics, Inc.
Common Stock
2019-12-31$10.82/sh+382→ 13,784 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2019-12-15$15.99/sh−576→ 11,492 total

Companies

Revance Therapeutics, Inc.
Chief Commercial Officer

Recent Filings

Address

C/O REVANCE THERAPEUTICS, INC 7555 GATEWAY BLVD

NEWARK, CA, 94560

View on SEC.gov